{
  "id": "fda_guidance_chunk_0302",
  "title": "Introduction - Part 302",
  "text": "have control of all essential documents and records generated by the investigator/institution before, during, and after the trial. 8.2 Before the Clinical Phase of the Trial Commences During this planning stage the following documents should be generated and should be on file before the trial formally starts. Title of Document Purpose Located in Files of Investigator/Institution Sponsor 8.2.1 INVESTIGATOR’S BROCHURE To document that relevant and current scientific information about the investigational product has been provided to the investigator X X 8.2.2 SIGNED PROTOCOL AND AMENDMENTS, IF ANY, AND SAMPLE CASE REPORT FORM (CRF) To document investigator and sponsor agreement to the protocol/amendment(s) and CRF X X 8.2.3 INFORMATION GIVEN TO TRIAL SUBJECT -INFORMED CONSENT FORM (including all applicable translations) To document the informed consent X X -ANY OTHER WRITTEN INFORMATION To document that subjects will be given appropriate written information (content and wording) to support their ability to give fully informed consent X X -ADVERTISEMENT FOR SUBJECT RECRUITMENT (if used) To document that recruitment measures are appropriate and not coercive X Contains Nonbinding Recommendations 8.2.4 FINANCIAL ASPECTS OF THE TRIAL To document the financial agreement between the investigator/institution and the sponsor for the trial X X 8.2.5 INSURANCE STATEMENT (where required) To document that compensation to subject(s) for trial-related injury will be available X X 8.2.6 SIGNED AGREEMENT BETWEEN INVOLVED PARTIES, e.g.: -Investigator/institution and sponsor -Investigator/institution and CRO -Sponsor and CRO -Investigator/institution and authority(ies) (where required) To document agreements X X X X X (where required) X X 8.2.7 DATED, DOCUMENTED APPROVAL/FAVORABLE OPINION OF INSTITUTIONAL REVIEW BOARD (IRB)/INDEPENDENT ETHICS COMMITTEE (IEC) OF THE FOLLOWING: 􀁸 Protocol and any amendments 􀁸 CRF (if applicable) 􀁸 Informed consent form(s) 􀁸 Any other written information to be provided to the subject(s) 􀁸 Advertisement for subject recruitment (if used) 􀁸 Subject compensation (if any) 􀁸 Any other documents given approval/favorable opinion To document that the trial has been subject to IRB/IEC review and given approval/favorable opinion. To identify the version number and date of the document(s) X X Contains Nonbinding Recommendations 8.2.8 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE COMPOSITION To document that the IRB/IEC is constituted in agreement with GCP X X (where required) 8.2.9 REGULATORY AUTHORITY(IES) AUTHORIZATION/APPROVAL/NOTIFICATION OF PROTOCOL (where required) To document appropriate authorization/approval/notification by the regulatory authority(ies) has been obtained prior to initiation of the trial",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 404544,
  "end_pos": 406080,
  "tokens": 512,
  "tags": [
    "design",
    "regulatory",
    "clinical_trial",
    "consent"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.699Z"
}